Inoue Hiroyuki, Toma Atsushi, Watanabe Nobuyuki, Ito Hiroshi, Ochiai Toshiya, Otsuji Eigo
Department of Surgery, North Medical Center Kyoto Prefectural University of Medicine.
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine.
Nihon Shokakibyo Gakkai Zasshi. 2018;115(10):905-913. doi: 10.11405/nisshoshi.115.905.
A 42-year-old male was referred to our hospital with bloody feces and lower back pain. He was diagnosed with unresectable gallbladder cancer with rectal metastasis (T3aN1M1, Stage IVB). The patient was administered gemcitabine plus cisplatin (GC). After nine courses of GC, computed tomography showed regression of the tumor and the patient's tumor marker levels had decreased. Therefore, curative resection was performed. Ten months after the operation, recurrence was observed in the rectal margin and GC was restarted. Because the total dose of cisplatin was 1040mg, we stopped cisplatin and continued to administer only gemcitabine (at the same dose). A follow-up examination 2 years after the operation showed no evidence of recurrence. Conversion therapy might be an effective multidisciplinary treatment for advanced gallbladder cancer that is initially unresectable. Herein, we report the case of a patient with advanced gallbladder cancer and rectal metastasis who was successfully treated by curative resection after chemotherapy;we also review the relevant literature.
